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Transcription factorsandchromatin-remodelingcom-
plexes are key determinants of embryonic stem
cell (ESC) identity. Here, we demonstrate that BRD4,
a member of the bromodomain and extraterminal
domain (BET) family of epigenetic readers, regulates
the self-renewal ability and pluripotency of ESCs.
BRD4 inhibition resulted in induction of epithelial-to-
mesenchymal transition (EMT) markers and commit-
ment to the neuroectodermal lineage while reducing
the ESC multidifferentiation capacity in teratoma as-
says. BRD4 maintains transcription of core stem cell
genes such asOCT4 andPRDM14 by occupying their
super-enhancers (SEs), large clusters of regulatory el-
ements, and recruiting to them Mediator and CDK9,
the catalytic subunit of the positive transcription
elongation factor b (P-TEFb), to allow Pol-II-depen-
dent productive elongation. Our study describes a
mechanism of regulation of ESC identity that could
be applied to improve the efficiency of ESC differ-
entiation.
INTRODUCTION
Embryonic stem cells (ESCs) rely on a small set of core pluripo-
tency transcription factors (TFs) to preserve self-renewal cap-
acity and cellular plasticity (Keramari et al., 2010; Mitsui et al.,
2003; Pesce and Scho¨ler, 2001). These cells possess a distinc-
tive ‘‘open’’ chromatin structure with abundant posttranslational
modifications on the N-terminal tails of histones, which allows
them to sustain a high level of transcriptional activity compared
to fully differentiated cells (Meshorer and Misteli, 2006). The
conformational state of the chromatin functions as a signal inter-234 Cell Reports 9, 234–247, October 9, 2014 ª2014 The Authorspreted by the transcriptional machinery to activate the expres-
sion of the core pluripotency TFs that maintain the ESC state
(Ding et al., 2009; Fazzio et al., 2008; Li et al., 2012; Morey
et al., 2012; Onder et al., 2012).
Bromodomain (BrD)-containing proteins function as key epi-
genome readers at the interface between chromatin remodeling
and transcriptional regulation (Haynes et al., 1992). In humans,
there are 61 predicted bromodomains in 46 proteins (Filippako-
poulos et al., 2012; Sanchez and Zhou, 2009), including chro-
matin regulators of the SWI/SNF superfamily of DNA helicases
(Tamkun et al., 1992), histone acetyltransferases (HATs) such
as CREB-binding protein (Bannister and Kouzarides, 1996;
Ogryzko et al., 1996) and TBP-associated factor 1 (Morinie`re
et al., 2009), as well as the bromodomain and extraterminal
domain (BET) family of transcriptional regulators (BRD2,
BRD3, BRD4, and BRDT). BRD2, BRD3, and BRD4 are ubiqui-
tously expressed, whereas BRDT expression is restricted to
testis (Jones et al., 1997). BET proteins play multiple roles in
transcription by binding to acetylated lysines and recruiting
chromatin-modifying enzymes that function as context-depen-
dent coactivators or corepressors (reviewed in Belkina and De-
nis, 2012). They serve as scaffolds for chromatin binding of
HATs, histone deacetylases, and components of the SWI/SNF
and Mediator complexes. In addition, BRD4 and BRDT interact
with the positive transcription elongation factor b (P-TEFb)
through their carboxy-terminal regions (Bisgrove et al., 2007).
Recent studies have demonstrated important roles of BET pro-
teins in development, inflammation, and cancer (reviewed in
Belkina and Denis, 2012). Instrumental to these studies has
been the availability of highly permeable, potent, and specific
small-molecule inhibitors, which have allowed probing of BET
functions in a variety of experimental systems (Segura et al.,
2013; Filippakopoulos et al., 2010; Nicodeme et al., 2010; Zhang
et al., 2012).
Our study reveals that BRD4 sustains ESC self-renewal
and controls cell fate decisions by positively regulating the
expression of pluripotency genes. BRD4 specifically governs the
transcriptional elongation of stem cell transcripts by occupying
their associated super-enhancers (SEs) and recruiting Mediator
and CDK9 to those regulatory elements, thus emerging as a
key regulator of the intricate gene expression network that main-
tains ESC identity.
RESULTS
BRD4 Is Required for Maintenance of ESC Identity
To investigate the role of BET proteins in the maintenance of
ESC identity, we inhibited BET activity by pharmacological and
genetic means. We used highly specific, cell-permeable small
molecules to effectively block acetylated lysine binding by BET
proteins (Borah et al., 2011; Zhang et al., 2012). MS436 is a
broad-range diazobenzene compound with high affinity for
some BrD-containing proteins (Figure S1A; Zhang et al., 2013).
MS417 is a thienotriazolodiazepine BrD inhibitor with high affinity
and specificity for the BrDs of BET proteins (Figure S1A and S1B)
and is structurally related to previously reported BET inhibitors,
JQ1 (Filippakopoulos et al., 2010) and GSK525762A (Nicodeme
et al., 2010). Treatment of human ESCs (hESCs) with either
MS436 or MS417 altered colony integrity and reduced alkaline
phosphatase (AP) activity, compared to vehicle- or fibroblast
growth factor (FGF)-treated cells (Figures 1A and 1B). Similar
results were obtained in murine ESCs (mESCs) treated with
BET inhibitors in the presence of leukemia inhibitory factor (LIF)
(Figures 1C and 1D). To dissect the relative contributions of
individual BET proteins to the observed morphological changes
of ESCs following BET inhibition, we independently silenced
BRD2, BRD3, and BRD4 by short hairpin RNA (shRNA)-medi-
ated transduction in both hESCs and mESCs (Figures S2A and
S2B). Depletion of BRD2 and BRD3 did not perturb ESC colony
formation (Figures 1E–1H). In contrast,BRD4 silencing disrupted
bothmouse and human ESC colony integrity, yielding a flattened
and dispersed morphology similar to that observed with BET in-
hibitors and characteristic of differentiating ESCs (Figures 1E–
1H). Similar results were obtained with an independent small
interfering RNA (siRNA)-mediated knockdown ofBRD4 in hESCs
(Figures S2C–S2E). Importantly, BET inhibition and BRD4 sup-
pression impaired ESC colony formation without overt induction
of apoptosis (Figure S2F; data not shown), indicating that chem-
ical or genetic inhibition of BRD4 is not detrimental to ESC
viability. We also observed that prolonged compound treatment
resulted in accumulation of ESCs in theG1 phase of the cell cycle
at the expense of S phase and cell proliferation (Figures 1I, S2G,
and S2H), which is consistent with the acquisition of a more-
differentiated phenotype. Finally, BET inhibition reduced the
ability of both human and murine ESCs to form colonies after
repeated passaging (Figures 1J and S2I); compound-treated
colonies that did form were only weakly positive for AP (Fig-
ure S2J). Collectively, these results demonstrate that BRD4 is
a key regulator of ESC maintenance.
BRD4 Positively Regulates the ESC Transcriptome
In deducing the mechanism by which BRD4 maintains the ESC
state, we reasoned that BRD4 was likely to regulate the expres-
sion of genes required for ESC identity. Global gene-expressionprofiling by RNA sequencing of compound- versus FGF-treated
hESCs confirmed the suppression of pluripotency transcripts
(Table S1) at day 1 post-compound treatment, even more pro-
nounced by day 5 (Figure 2A; Table S2). Gene set enrichment
analysis of downregulated genes revealed enrichment inmultiple
ESC-related gene categories following compound treatment,
indicating that the stem cell gene network is significantly per-
turbed by BET inhibition (Figure 2B). The expression of key deter-
minants of ESC identity, includingOCT4,NANOG, and PRDM14,
was rapidly suppressed following compound treatment in hu-
man and mouse ESCs cultured even in the presence of FGF
(hESCs; Figure 2C) or LIF (mESCs; Figure 2D), indicating that
BET inhibition can counteract the extracellular signals that help
to maintain ESCs in an undifferentiated state in vitro. Consis-
tently, we found that OCT4 protein levels were reduced in hESCs
following BET inhibition (Figures 2E and 2F). The rapid loss of
expression of stem cell factors upon BET inhibition preceded
the defects in cell cycle progression associated with the acquisi-
tion of a more differentiated phenotype (Figures 1I, S2G, and
S2H), indicating that the former is not a result of the latter. Similar
results were obtained in an established human induced pluripo-
tent stem cell (iPSC) line (Papapetrou et al., 2009; Figure S3A)
and in a pluripotent embryonic carcinoma cell line (NTERA-2;
Figure S3B), indicating that the effects of BET inhibition on plu-
ripotency gene expression are not restricted to ESC lines. Treat-
ment of hESCs with the BET inhibitor JQ1 (Filippakopoulos et al.,
2010) yielded comparable suppression of stem cell genes to
MS417 treatment (Figure S3C). Moreover, RNAi-mediated
BRD4 silencing led to reduced expression of key determinants
of stem cell identity (e.g., OCT4, PRDM14, and NANOG) in
human and mouse ESCs (Figures 2G and 2H), mimicking the
effects of compound treatment. Interestingly, the expression
of housekeeping genes was mostly unaffected upon BRD4
silencing (Figures 2G and 2H), suggesting a specific transcrip-
tional regulation of stem cell genes by BRD4. The expression
of stem cell genes was also suppressed in hESC, established
iPSC, and NTERA lines following siRNA-mediated BRD4 deple-
tion (Figures S3D–S3F). Our findings indicate that BRD4 specif-
ically contributes to the transcriptional program that maintains
the expression of many stem cell genes and ESC identity.
Surprisingly, the expression of c-MYC, a positive regulator of
proliferation and survival, was not downregulated after BET inhi-
bition in either mouse or human ESCs (Figure S3G and S3H),
despite being suppressed by compound treatment in cancer
settings (Dawson et al., 2011; Zuber et al., 2011; Delmore
et al., 2011). This suggests that c-MYC transcriptional regulation
by BRD4 may be context dependent and, in the case of ESCs,
BRD4 independent.
BRD4 Regulates Pluripotency of ESCs and
Neuroectodermal Lineage Commitment
We next investigated whether BRD4 inhibition results in ESC
differentiation together with suppression of stem cell genes
and loss of self-renewal capacity. Compound treatment of
ESCs modulated the expression of genes involved in epithelial-
to-mesenchymal transition (EMT) (Figures 3A and 3B), a defining
feature of ESCs undergoing differentiation. Accompanying the
emergence of an EMT signature, we observed an enrichmentCell Reports 9, 234–247, October 9, 2014 ª2014 The Authors 235
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Figure 1. BRD4 Regulates ESC Identity
(A) Representative bright field images (upper panel) of hESCs treated for 3 days with BET inhibitors compared to FGF- or vehicle-treated cells. Alkaline Phos-
phatase (AP) staining following treatment is shown in bottom panel.
(B) Quantification of AP-positive hESC colonies following FGF, vehicle, or compound treatment.
(C) Bright field images (upper panel) and AP staining (bottom panel) of mESCs treated with BET inhibitors for 3 days in the presence of LIF.
(D) Quantification of AP-positive mESC colonies following 3 days of compound treatment.
(legend continued on next page)
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Figure 2. BRD4 Regulates the Expression of Stem Cell Genes
(A) Scatter plots of gene expression at 24 hr and 120 hr in hESCs following MS436 treatment. Each point corresponds to a differentially expressed gene in
compound-treated versus FGF-treated hESCs. Red dots indicate genes in the ESC gene categories (Table S1). Black dots represent stem cell genes validated
throughout the manuscript. q value cutoff used throughout the analysis = 0.01.
(B) Gene set enrichment analysis of downregulated genes at 24 hr and 120 hr following BET inhibition, according to MSigDB.
(C and D) Time course expression of stem cell genes in hESCs (C) and mESCs (D), cultured in the presence of FGF (C) or LIF (D), upon compound treatment
relative to vehicle-treated cells (dashed line), as detected by qRT-PCR.
(E) Effect of BET inhibitor treatment (3 days) on OCT4 protein levels as detected by immunoblotting. Tubulin is used as a loading control.
(F) Effect of compound treatment on hESC colony morphology (DAPI) and OCT4 protein expression as detected by immunostaining. The scale bar represents
100 mm.
(G and H) Relative mRNA expression of the indicated stem cell and housekeeping genes (HK) in hESCs (G) and mESCs (H) after BRD4 genetic depletion, as
detected by qRT-PCR. Dashed lines represent nontargeting control (NTC)-transduced cells.
Error bars represent SD. See also Tables S1 and S2 and Figure S3.of neuroectodermal differentiation markers (e.g., NES, NCAD,
and SOX1) relative to markers of other lineages in both hESCs
(Figures 3B and 3C) and mESCs (Figures S4A and S4B), indi-
cating lineage specificity associated with BET inhibition. Con-
sistently, individual silencing of BRD4 mimicked the preferential
regulation of EMT and neuroectodermal markers over other line-
ages observed following pharmacologic BET inhibition in human
(Figure 3D) and mouse ESCs (Figure S4C). BET inhibitor treat-(E–H) Bright field images of hESC (E) and mESC (G) colonies following BRD2, BR
colonies is shown in (F) and (H), respectively. NTC, nontargeting control.
(I) Cell-cycle analysis of hESCs following BET inhibitors treatment at the indicate
(J) Self-renewal capacity of vehicle- and compound-treated hESCs passaged onm
AP, alkaline phosphatase; ND, not detected. *p% 0.05; **p% 0.01; ***p% 0.001.
and S2.ment of ESCs significantly affected both the number and
morphology of embryoid bodies (EBs) (Figures S5A and S5B),
indicating that BRD4 activity is required for the formation of tridi-
mensionally organized EBs. Moreover, BET inhibition resulted in
suppression of stem cell genes (Figure S5C) and induction of
neuroectodermal lineage genes over genes of other lineages in
EBs formation assay (Figure S5D), highlighting the specific line-
age commitment following BET inhibition.D3, and BRD4 suppression. Percentage of undifferentiated hESCs and mESC
d time points as determined by FACS analysis.
itotically inactivatedMEFs in the presence of FGF asmeasured by AP staining.
The scale bar represents 100 mm. Error bars represent SD. See also Figures S1
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Figure 3. BET Inhibition and BRD4 Suppression Lead to EMT Induction and Neuroectodermal Lineage Commitment of ESCs
(A) Downregulation of the epithelial marker E-cadherin (ECAD) in FGF-, vehicle-, or compound-treated hESCs, as detected by immunofluorescence analysis after
5 days of compound treatment. The scale bar represents 100 mm.
(B) Expression over time of a panel of EMT, neuroectodermal, and mesendodermal markers in hESCs following BET inhibition, as detected by qRT-PCR. Dashed
line represents expression in vehicle-treated cells.
(C) Gene set enrichment analysis of upregulated genes following 5 days of compound treatment in Gene Ontology terms compared to FGF-treated hESCs.
(D) Expression of EMT (red) and mesendodermal (green) genes following BRD4 depletion in hESCs, as detected by qRT-PCR. Dashed line represents
NTC-transduced hESCs.
(E) Representative images of teratomas derived from NTC and shBrd4-transduced mESCs. The scale bar represents 1 cm.
(F) Weight distribution of NTC- and Brd4-depleted mESC-derived tumors. Horizontal line represents the median value.
(legend continued on next page)
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A defining trait of ESC pluripotency is the ability to form tera-
tomas in vivo. To determine if BRD4 regulates pluripotency
in vivo, ESCswere efficiently transducedwith either nontargeting
control (NTC) or shBrd4 lentiviral vectors and injected subcuta-
neously into immunodeficient (Rag2/) mice. After 4 weeks,
we found that Brd4 depletion significantly reduced both the
size and number of engrafted teratomas (Figures 3E and 3F). His-
tological analysis of shBrd4- versus control-derived tumors re-
vealed a reduced representation of meso- and endodermal
germ layers relative to neuroectodermal lineage (Figure 3G; Ta-
ble S3). This phenotype could not be explained merely by
reduced proliferation as shown by the presence of Ki67-positive
cells in Brd4-depleted tumors (Figure 3H, top panels). Further-
more, shBrd4-derived tumors displayed induction of neuro-
ectodermal markers (i.e., NeuN), recapitulating the effects of
BET inhibition in vitro in lineage commitment (Figure 3H, bottom
panels). Together, these findings indicate that Brd4 is a critical
mediator of ESC pluripotency in vivo.
Next, we investigated the mechanisms by which BRD4 inhibi-
tion results in ESCs commitment toward the neuroectodermal
lineage. Considering that, in addition to having a critical role in
pluripotency, Oct4 also acts as a repressor of neuroectodermal
specification (Thomson et al., 2011; Wang et al., 2012), we hy-
pothesized that its downregulation following BRD4 inhibition
may be responsible for the induction of neuroectodermal line-
age. Therefore, ectopic Oct4 expression should prevent the
induction of the neuroectodermal lineage upon compound treat-
ment. Indeed, we found that ectopic Oct4 expression (Figure 3I)
in ESCs treated with BET inhibitors restricted the induction of
EMT and neuroectodermal markers (Figure 3J). Nevertheless,
Oct4 upregulation in this context did not rescue the expression
of stem cell genes and it was unable to induce the levels of mes-
oendodermal markers (Figure 3K; data not shown). In sum, these
findings indicate that the neuroectodermal lineage commitment
of ESCs following BRD4 inhibition is at least partially due to
downregulation of Oct4 and imply that BRD4 controls both
ESC identity and cell fate decisions via regulation of key pluripo-
tency genes.
BRD4 Occupies and Transcriptionally Regulates
Super-Enhancer-Associated Stem Cell Genes
In order to dissect the mechanisms by which BRD4 regulates
pluripotency gene expression, we performed chromatin immu-
noprecipitation sequencing (ChIP-seq) for BRD4 in vehicle- or
compound-treated hESCs grown in the presence of FGF in
two independent, highly reproducible (R2 = 0.815) biological rep-
licates. Using stringent parameters (see Experimental Proce-
dures section), we identified 4,026 BRD4-binding peaks that
were common to both biological replicates. We first examined
the distribution of BRD4 protein occupancy at defined regions(G) Representative micrographs of hematoxylin and eosin sections of NTC or sh
(H) Expression of Ki67 andNeuN in shBrd4-derived tumors compared to NTC-deri
200 mm.
(I)Oct4 expression levels following compound treatment in mESCs transduced wi
(J) Expression by qRT-PCR of EMT and neuroectodermal genes (Ncad and Nest
(K) Expression by qRT-PCR of mesendodermal genes (Brachyury and Cdx2) follo
Error bars represent SD. *p% 0.05. See also Table S3 and Figures S4 and S5.relative to gene elements in vehicle-treated hESCs by classifying
the identified peaks into (1) 1 kb transcription start site (TSS)-
flanking regions of known transcripts; (2) gene body regions,
excluding any overlapping regions with (1); or (3) upstream re-
gions of 10 kb to 100 kb, excluding any overlapping regions
with either (1) or (2). The remaining genomic loci were classified
as intergenic regions. In vehicle-treated cells, BRD4 occupied
gene bodies and TSSs (31.9% and 31.1%; Figure 4A) and was
also present at upstream regions (31.1%; Figure 4A), suggesting
a possible binding to regulatory elements in the genome in addi-
tion to promoters and gene bodies. BRD4 occupancy in hESCs
was analyzed 6 hr after treatment to identify early compound-
responsive elements. BET inhibition consistently resulted in
robust and global displacement (defined as absence of peak in
treatment; see Experimental Procedures) of BRD4 from the
vast majority of the occupied genomic loci common to the two
biological replicates (Figures 4B and 4C), indicating that our
small-molecule compounds are potent displacers of BRD4
from chromatin. Gene set enrichment analysis of genes from
which BRD4was displaced following treatment revealed a signif-
icant enrichment in stem cell gene categories, enforcing the
concept that BRD4 regulates the stem cell gene transcriptional
network (Figure 4D; Table S4).
Recently, large enhancer domains called SEs have been iden-
tified at key cell identity genes (Whyte et al., 2013; Hnisz et al.,
2013). We found that BRD4 localizes at SEs of stem cell genes,
such asOCT4 andPRDM14, in vehicle-treated hESCs and is dis-
placed from them following compound treatment (Figures 4E and
4F). Despite BRD4 peak signal intensity being similar in SEs and
typical enhancers (TEs) in hESCs (Figure 4G), more BRD4-bind-
ing peaks were found in SEs than in TEs. Indeed, BRD4-binding
peaks reside in 42.98% of SEs (294 out of 684 SEs) compared
to 9.28% TEs (587 out of 6,322 TEs; Figure 4H), after controlling
for BRD4 peak signal intensity and enhancer size. These data
suggest that BRD4 may specifically bind and regulate SE-asso-
ciated genes, which are key stem cell identity genes. In further
support of preferential regulation of SE-associated genes
by BRD4, integration of ChIP-seq data with changes in gene
expression revealed that, of all BRD4 targets, those associated
with SEs were mostly downregulated upon BRD4 displacement,
whereas the majority of non-SE-associated genes remained
constant (Figure 4I). These findings indicate that SE-associated
genes aremore dependent on BRD4 binding for their active tran-
scription than genes that do not associate with SEs.
Expression of SE-Associated Genes Depends on BRD4-
Mediated Recruitment of Mediator Complex at SEs
The Mediator complex is a transcriptional activator of the
pluripotency gene network that represents a potentially impor-
tant player in BRD4-mediated transcriptional regulation ofBrd4-mESCs-derived tumors. EC, ectoderm; EN, endoderm; M, mesoderm.
ved teratomas as detected by immunohistochemistry. The scale bar represents
th an empty vector orOct4 cDNA-expressing vector, as detected by qRT-PCR.
in) following BET inhibition in control and Oct4-expressing mESCs.
wing BET inhibition in control and Oct4-expressing mESCs.
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Figure 4. BRD4 Occupies and Regulates Super-Enhancer-Associated Genes
(A) Genome-wide distribution of BRD4 in 1-kb-flanked TSS regions, gene bodies (excluding flanked TSS regions), upstream (up to 100 kb and excluding flanked
TSSs and gene bodies), and intergenic regions (excluding all of the above) by ChIP-seq.
(B) Number of BRD4-binding peaks common to two biological replicates after 6 hr of vehicle or MS417 treatment.
(C) Heatmap representation of ChIP-seq binding for BRD4 peaks common to two independent biological replicates before and after BET inhibition, rank ordered
form the most BRD4 to lowest BRD4. Immunoglobulin G (IgG) is shown as a negative control for enrichment.
(D) Gene set enrichment analysis of BRD4 target genes (e.g., genes from which BRD4 is displaced following BET inhibition [top ten categories are shown]).
(E and F) Genome browser representations of BRD4 and IgG ChIP-seq reads at stem cell genes [i.e., OCT4 (E) and PRDM14 (F)], in FGF-cultured hESCs treated
with vehicle or MS417. Black bars indicate super-enhancers (SEs) (Hnisz et al., 2013). Arrows indicate direction of transcription. Insert represents a close up for
BRD4 and IgG binding at PRDM14 SE before and after treatment. Chromosomal locations are indicated.
(G) Read density representation of global BRD4 occupancy at typical enhancer (TE) and SE elements. The x axis shows the center of TE regions flanked by 5 kb as
well as the start and end of SE regions flanked by 5 kb of adjacent sequence. The y axis indicates reads per kilobase of transcript permillion readsmapped (RPKMs).
(H) Table indicates the percentage and total number of BRD4-overlapping TEs and SEs at BRD4 peak signal distributions comparable between TEs and SEs. TEs
were extended upstream and downstream from their centers such that their size equals the mean size of SEs. Control (ctrl) refers to the percent of peaks at SEs/
TEs if the BRD4-displaced regions were randomly distributed along the genome.
(I) Histogram indicates the percentage of BRD4 target genes that are downregulated, constant, and upregulated in SE- and non-SE-associated gene categories
upon compound treatment.
See also Tables S4 and S5 and Figure S7.SE-associated stem cell genes. We found that MED1 (Core
Mediator) and MED12 (CDK8-module) subunits localize at both
SEs and promoters of stem cell genes in hESCs (i.e., OCT4
and PRDM14; Figures 5A–5D). Notably, the binding of MED1
and MED12 at SEs, but not at promoters, was significantly
reduced by BRD4 inhibition (Figures 5A–5D), suggesting that
BRD4 may act as a docking site for the Mediator complex at
SEs of stem cell genes, thus regulating their expression. Consis-
tent with the observation that c-MYC was not downregulated
following BRD4 inhibition (Figure S3G), we did not find a SE
associated with c-MYC in hESCs. In this non-SE-associated
gene, Mediator occupancy was not altered by compound treat-
ment (Figures 5E and 5F). Importantly, displacement of Mediator
from SEs upon compound treatment was not due to reduced
levels of MED1 and MED12 following BRD4 inhibition in hESCs240 Cell Reports 9, 234–247, October 9, 2014 ª2014 The Authorsand mESCs (Figure 5G). Silencing of Mediator subunits resulted
in suppression of stem cell genes, thus recapitulating the effects
of BRD4 inhibition on the ESC transcriptional network (Fig-
ure 5H). The expression of c-Myc was also inhibited following
Med1 and Med12 depletion (Figure 5H), suggesting that Medi-
ator is a positive transcriptional regulator of c-MYC expression
but independently of BRD4. Altogether, these data indicate
that the expression of SE-associated stem cell genes relies on
BRD4-dependent binding of Mediator-containing complexes at
SEs.
BRD4 Is Required for Productive Elongation of SE-
Associated Genes
In addition to Mediator, BRD4 has been found to interact with
CDK9, the catalytic subunit of the P-TEFb transcriptional
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Figure 5. Mediator Is Required for BRD4-
Dependent Regulation of SE-Associated
Genes
(A–F) ChIP analysis of MED1 and MED12 binding
at enhancer regions and promoters (prom) of SE-
associated stem cell genes [OCT4 (A and B) and
PRDM14 (C and D) and a non-SE-associated
gene, c-MYC (E and F)] in hESCs following BET
inhibition. Bar graphs represent the mean enrich-
ment relative to input, and error bars reflect SD of a
representative experiment run in triplicate.
(G) Expression levels of MED1 and MED12 by
qRT-PCR following BET inhibition in hESCs and
mESCs.
(H) Expression of the indicated genes in shMed1
and shMed12 mESCs compared to NTC-trans-
duced cells as detected by qRT-PCR.
See also Figure S6H for primers design.elongation complex (Bisgrove et al., 2007; Dawson et al., 2011).
To study whether BRD4 regulates the expression of SE-associ-
ated stem cell genes via productive transcriptional elongation,
we performed ChIP assays for CDK9, as well as two elongation
marks, the phosphorylated Pol II at Ser2 (pS2) and H3K36me3.
We found that together with BRD4, CDK9 is more associated to
SE of stem cell genes (e.g., OCT4 and PRDM14; Figures 6A
and 6B) than to genes bearing regular enhancer elements
(e.g., c-MYC; Figure 6C). BRD4 inhibition resulted in dramatic
loss of CDK9 from the SEs and promoters (Figures 6A and
6B). Next, we investigated whether loss of BRD4 and CDK9
from SEs results in reduced levels of elongation marks in
gene bodies (GBs) of SE-associated stem cell genes.
H3K36me3 and Pol II pS2 were reduced following compoundCell Reports 9, 234–24treatment at the gene bodies of OCT4
and PRDM14 (Figures 6D and 6E).
Conversely, c-MYC, a non-SE-associ-
ated gene, did not display any loss of
elongation marks (Figure 6F), consistent
with its unreduced expression levels
following BRD4 inhibition (Figure S3G).
BRD4 silencing was sufficient to recapit-
ulate the effects of BET inhibition on the
transcriptional elongation of SE-associ-
ated stem cell genes and did not affect
the levels of elongation marks at c-MYC
gene body (Figures 6G–6I). The levels
of active transcription and initiation
marks, such as H3K4me3 and Pol II
pS5, were mostly unaffected by BET in-
hibition at both SE and non-SE-associ-
ated genes (Figures S6A–S6C). Further-
more, levels of H4K5 acetylation, one of
the docking sites for BET binding to
chromatin (Filippakopoulos et al., 2012),
remained unchanged upon compound
treatment (Figures S6D–S6F). These
findings suggest that BRD4 controls
SE-associated stem cell gene expres-sion by regulating their transcriptional elongation rather than
transcriptional initiation or histone acetylation.
Next, we investigated whether reduced elongation after BRD4
inhibition was mainly due to a defective Pol II pause release at
the TSS and/or to loss of elongating Pol II from the gene body.
For that, we analyzed genome-wide occupancy of Pol II in
vehicle- or compound-treated hESCs and calculated the Pol II
traveling ratio (Pol II at the TSS over the gene body) in SE and
non-SE-associated genes that were downregulated following
BRD4 inhibition. The analysis presented below was performed
(1) on all SE versus non-SE genes and (2) on a subset of SE
and non-SE genes of similar expression levels before treatment.
Both analyses supported our conclusions, but for clarity, only
the latter is presented. We found that the traveling ratios of7, October 9, 2014 ª2014 The Authors 241
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Figure 6. BRD4 Inhibition Impairs the Transcriptional Elongation of SE-Associated Stem Cell Genes
(A–C) ChIP analysis of the elongation factor CDK9 at SEs and promoters of OCT4 (A), PRDM14 (B), and c-MYC enhancer and promoter (C) following compound
treatment. IgG was used as control. Bar graphs represent the mean enrichment relative to input, and error bars reflect SD of a representative experiment run in
triplicate.
(D–F) ChIP analysis of the elongation marks H3K36me3 and Pol II-pS2 on gene bodies (GBs) of SE-associated genes, OCT4 (D) and PRDM14 (E), and non-SE-
associated gene, c-MYC (F), following compound treatment.
(G–I) ChIP analysis of the elongation marks H3K36me3 on GB of OCT4 (G), PRDM14 (H), and c-MYC (I) in BRD4-depleted cells compared to NTC-transduced
hESCs.
(J) Traveling ratio distribution across SE- or non-SE-associated transcripts of similar expression before treatment and similarly downregulated after treatment.
The initiating regions are defined as ±300 bp around the TSS, and the elongating regions are defined as +300 bp from the TSS to 3,000 bp after the transcript
ends.
(K) Distribution of fold changes of Pol II densities (normalized by total number of reads per treatment) at TSSs following compound treatment in SE- and non-SE-
downregulated transcripts.
(L) Distribution of fold changes of Pol II densities (normalized by total number of reads per treatment) at GBs following compound treatment in SE- and non-SE
genes, downregulated following MS417 treatment. Dashed lines indicate the fraction of genes with reduced Pol II occupancy at gene bodies in the two gene
categories.
ns, not significant; ***p% 0.001. See also Figure S6.both SE and non-SE genes significantly increase after com-
pound treatment (p < 0.001; Wilcoxon test; Figure 6J). An in-
crease in traveling ratio could be explained by Pol II stalling at
the TSS, by a decrease in Pol II binding throughout the gene
body with no increase at TSS, or by a combination of both fea-
tures. We found that Pol II stalls at the TSS in a high percentage
of both downregulated SE- and non-SE-associated genes
following BRD4 inhibition (Figure 6K). Conversely, we found
that a higher fraction of downregulated SE-associated genes242 Cell Reports 9, 234–247, October 9, 2014 ª2014 The Authorsdisplayed a significant Pol II loss from the gene body than down-
regulated non-SE-associated genes upon BRD4 displacement
(Figure 6L; snapshots of Pol II binding at OCT4 and PRDM14
in Figure S6G; primers design for ChIP experiments in Figures
5 and 6 are indicated in Figure S6H). This finding suggests
that concomitant increase of Pol II stalling with loss of Pol II
from the gene body is a unique feature of SE-associated genes
and may be responsible for their defective transcriptional elon-
gation following BRD4 inhibition.
AB
Figure 7. Model Depicting the Effects of
BET Inhibition on the Binding of MED,
BRD4, CDK9, and Pol II at SE-Associated
Stem Cell Genes and Non-SE-Associated
Genes
(A) SE-associated stem cell genes depend on the
cooperative binding of BRD4, MED, and CDK9 at
their SEs for productive transcription elongation
(Pol II pS2 and H3K36me3). BRD4 also localizes in
the gene body, most likely to help the traveling of
Pol II through nucleosomes. Compound treatment
displaces, together with BRD4, MED, and CDK9,
resulting in Pol II stalling at TSSs and reduced
elongating Pol II in the gene body of stem cell
genes.
(B) The vast majority of TE-associated genes does
not rely on BRD4 binding for their elongation and
are insensitive to BRD4 inhibition. Transcription
factors and chromatin remodelers rather than
BRD4 may be responsible for the expression of
TE-associated genes.We envision a model in which BRD4 recruits SE-associated
complexes at SEs of stem cell genes, thus allowing the progres-
sion of a promoter-proximal Pol II through the gene body
to achieve productive elongation (Figure 7A). Meanwhile, the
transcriptional elongation of non-SE-associated genes remains
mostly unperturbed by BRD4 inhibition (Figure 7B). Downregula-
tion of the small percentage of non-SE-associated genes
following BRD4 inhibition is mainly due to increased Pol II at
the TSS rather than to loss of elongating Pol II throughout the
gene body. Collectively, our findings support a specific regula-
tion of transcriptional elongation of stem cell genes that relies
on BRD4-dependent binding of Mediator and CDK9 to SEs to
sustain ESC identity.Cell Reports 9, 234–24DISCUSSION
The role of BET proteins as chromatin
readers and transcriptional regulators of
the ESC gene network remains unex-
plored. BET family members display
similar structure and are conserved
throughout evolution. When we compared
the effect of BET inhibition on BRD2-,
BRD3-, and BRD4-binding peaks, we
found that compound treatment results in
robust and global displacement of BRD2
and BRD3, as well as BRD4, from the
vast majority of the occupied genomic
loci (Figures 4B, 4C, and S7A–S7D),
demonstrating that, by interfering with the
binding of BET proteins to acetylated his-
tones, small-molecule compounds act as
potent displacers of all members of the
BET family of proteins from the chromatin.
Geneset enrichment analysis ofBRD2and
BRD3 target genes displaced by com-
pound treatment did not reveal a signifi-
cant enrichment in stem cell gene cate-
gories (Figures S7E and S7F; Table S5), indicating that BRD4,
not BRD2 or BRD3, is required to maintain ESC state. In agree-
ment with this,BRD2 orBRD3 silencing did not affect ESC colony
morphology (Figures 1E–1H) or the expression of stem cell genes
(Figure S7G). Altogether, our data strongly suggest that, in the
context of ESCs, BET inhibition effects are mostly due to BRD4
displacement and that, of all BET members, BRD4 acts as the
most important regulator of ESC identity. Consistent with a role
forBRD4asakeymediator of ESCs identity,Brd4-nullmouse em-
bryos display postimplantation lethality that was attributed to
degeneration of the inner cell mass (Houzelstein et al., 2002).
Meanwhile, Brd2-null animals survive implantation and die at a
later embryonic stage of developmental abnormalities unrelated7, October 9, 2014 ª2014 The Authors 243
tomaintenanceof the innercellmass (Shangetal., 2009), confirm-
ing our results that Brd2 is not essential for ESC state mainte-
nance. A Brd3 knockout mouse has not yet been reported, so
role(s) of Brd3 in development remains unclear.
Self-renewal capacity of ESCs is tightly coupled to their prolif-
erative potential. BET proteins, in particular BRD4, play essential
roles in cell-cycle progression (You et al., 2009) and mitosis
(Zhao et al., 2011), thus raising the possibility that BET inhibitor
effects on ESC pluripotency could be explained by cell-cycle
arrest and compromised cell viability. We do find that prolonged
exposure to BET inhibitors and BRD4 depletion results in re-
duced proliferation of ESCs, which may contribute to the sig-
nificantly smaller size of teratomas generated following Brd4
depletion. However, time course analyses of vehicle- and com-
pound-treated ESCs demonstrated that changes in core plurip-
otency gene expression occurred within a few hours of BET
inhibitor treatment, substantially preceding proliferation arrest
and establishment of a differentiated state. These findings distin-
guish BRD4 as key regulator of cell identity of ESCs, rather than a
mere cell-cycle regulator.
Our findings indicate that BRD4 chemical and genetic inhibi-
tion result in loss of the ESC state while driving lineage specifica-
tion. The observed EMT and neuroectodermal commitment over
other lineages pointed to the possibility that BRD4may be exert-
ing repressive functions on differentiation genes of this lineage.
However, we did not find a significant enrichment of BRD4 in
EMT or differentiation genes in our ChIP-seq data sets, suggest-
ing that BRD4 does not directly repress neuroectodermal differ-
entiation genes. Alternatively, transcriptional induction of EMT
and differentiation genes following BRD4 inhibition could be
explained by regulation of stem cell genes known to directly
repress developmental genes and control germ layer fate selec-
tion (Thomson et al., 2011; Ma et al., 2011). Consistent with the
role of Oct4 as an inhibitor of the neuroectodermal lineage,
ectopic expression of Oct4 in ESCs limited the induction of neu-
roectodermal differentiation genes by BET inhibitors. These re-
sults suggest that the increased expression of neuroectodermal
lineage markers upon BET displacement might be explained by
the BET-dependent regulation of Oct4 (and possibly other neu-
roectodermal inhibitors).
Our study reveals that, relative to housekeeping genes, stem
cell genes particularly rely on BRD4 occupancy for their ex-
pression. A unique chromatin conformation or pattern of histone
modifications (Filippakopoulos et al., 2012) may favor BRD4-
dependent recruitment of transcriptional complexes to stem
cell genes over other gene categories. Recently, SEs have
been identified at key cell identity genes in ESCs and other cell
types (Hnisz et al., 2013; Whyte et al., 2013). Interestingly, our
study reveals a disproportionate occupancy of BRD4 at SEs
compared to TEs in hESCs. In addition, our discovery that,
following BET inhibition, genes associated with SEs are much
more frequently downregulated than non-SE-associated genes
suggests that SE occupancy and recruitment of transcriptional
coregulators may explain the specificity of stem cell gene regula-
tion by BRD4. Master transcriptional regulators have also been
described at SEs in ESCs (Hnisz et al., 2013). Protein-protein in-
teractions of BRD4 with ESC transcription factors at SEs may
also explain the BRD4-dependent specific regulation of stem244 Cell Reports 9, 234–247, October 9, 2014 ª2014 The Authorscell genes. The multisubunit modular complex Mediator, known
to regulate chromatin looping for gene activation (Poss et al.,
2013), was enriched at SEs, and its depletion resulted in downre-
gulation of SE-associated genes (Hnisz et al., 2013; Whyte et al.,
2013). Because the Mediator complex lacks a DNA-binding
domain, we hypothesize that BRD4, with its ability to bind acety-
lated lysines, recruits Mediator at SEs. Consistently, proteomics
studies have revealed the direct interaction between BRD4 and
Mediator complex (Dawson et al., 2011).
c-MYC is a proliferation-associated gene that regulates ESC
self-renewal and survival. c-MYCwas found to be a BRD4 target
and modulated in response to BET inhibition in multiple cancer
settings (Dawson et al., 2011; Zuber et al., 2011; Delmore et al.,
2011; Love´n et al., 2013). Surprisingly, there is no SE associated
to c-MYC in hESCs (Hnisz et al., 2013). Compound treatment did
not affect the expression of c-MYC in ESCs and did not displace
Mediator-containing complexes from its enhancer, suggesting a
unique, BRD4-independent regulation of c-MYC in ESCs. How-
ever, our gene set enrichment analysis of BRD4 target genes
identified c-MYC target genes as BRD4 bound and downregu-
lated following compound treatment (data not shown), suggest-
ing that, in ESCs, BRD4 may directly regulate the expression of
MYC target genes that may rely on BRD4 binding to their SEs.
Notably, BRD4 was the BET family member found to be the
most significantly enriched at SEs over TEs, compared to
BRD2 and BRD3, reinforcing the hypothesis that SE-associated
stem cell genes may dependmore on BRD4 than BRD2 or BRD3
for their expression. The close similarity among the bromodo-
mains of BET members suggests that their functional disparity
in ESC maintenance, with BRD4 being essential, does not lie in
the bromodomains but most likely in the extraterminal protein-
protein interaction domain and the long unstructured C-terminal
domain (CTD), unique to BRD4. In support of this concept, BRD4
was shown to be part of the super elongation complex in amodel
of mixed-lineage-leukemia-fusion leukemia (Dawson et al.,
2011). In particular, the CTD of BRD4 was reported to interact
and activate P-TEFb (CDK9/cyclin T1) to elicit full transcription
(Bisgrove et al., 2007), whereas an atypical kinase domain
residing between its bromodomains was shown to directly phos-
phorylate Pol II at position S2 to ensure productive elongation
(Devaiah et al., 2012). Our study reveals that the P-TEFb subunit,
CDK9, binds SEs and promoters of stem cell genes together with
BRD4 and is displaced following BET inhibition. Because CDK9
activity depends on its acetylation status (Fu et al., 2007), BRD4
may bind preferentially to the acetylated form of CDK9 at SEs
and sustain its kinase activity during transcriptional elongation.
BRD4 has been described as a Pol II pause release factor neces-
sary for gene expression (Anand et al., 2013). Interestingly, the
evidence that an increased Pol II pausing index in the majority
of downregulated SE-associated stem cell genes is due to
concomitant stalled Pol II at the TSSs and loss of Pol II from
the gene body suggests that both events contribute to the
nonproductive elongation of stem cell genes following BRD4 in-
hibition. One intriguing possibility is that loss of elongating Pol II
from the gene body of SE-associated stem cell genes following
BRD4 displacement might be due to lack of the previously re-
ported BET chaperone activity through acetylated nucleosomes
(LeRoy et al., 2008).
We present a model in which BRD4 binds SEs, recruits Medi-
ator and CDK9 at those regulatory elements, and allows Pol II
binding throughout the gene body of SE-associated pluripotency
genes for their productive elongation. This study provides evi-
dence that the expression of stem cell genes relies on a distinctly
productive transcriptional elongation and places BRD4 at the
center of a hub that recruits the transcriptional machinery to lo-
cus-specific open chromatin, thus connecting these two main
regulators of stem cell identity and cell fate decisions.
EXPERIMENTAL PROCEDURES
Cell Culture
mESCs were a kind gift from Dr. Ihor Lemischka (Mount Sinai School of Med-
icine) to I.A. Theywere passaged andmaintained on gelatin-coated dishes or in
coculture with mitomycin C (MITC)-treated mouse embryo fibroblasts (MEF)
(GlobalStem) in presence of LIF (ESGRO-LIF) under previously described con-
ditions (Schaniel et al., 2009). H9 hESCs were purchased from Wicell Institute
and maintained in coculture with MITC-treated MEFs in the presence of FGF
(10 ng/ml; R&D) under conditions described by the supplier. hESCs were
plated on Matrigel (BD Pharmingem)-coated plates in the presence of condi-
tioned medium from MITC-treated MEFs, FGF (10 ng/ml; R&D Systems), and
ROCK inhibitor (10 mM; Stemgent) for 48 hr before compound treatment to
allow hESCs to resume growth following single-cell suspension with Accutase
(Innovative Cell Technologies). NTERA-2 cl.D1, 293T cells were purchased
fromATCCand grown under standard tissue culture conditions. Human iPSCs,
a kind gift of Drs. Mark J. Tomishima and Michel Sadelain (Papapetrou et al.,
2009), were cultured under standard hESC conditions. MS436 was used at
10 mM, and MS417 was used at 250 nM concentration throughout the study.
DMSO was used as a vehicle control for compounds. (+) JQ1 enantiomers
were used at 500 nM concentration for 6 hr.
Alkaline Phosphatase Staining
Cells were fixedwith 4% formaldehyde and stained according to themanufac-
turer’s protocol (Alkaline Phosphatase Detection kit; Millipore).
Self-Renewal Assay
mESCs were trypsinized (Trypsin; GIBCO), and hESCs were treated with Ac-
cutase and plated on MITC-MEFs-coated 6-well plates (1.5 3 105 cells per
well) in complete ESC media containing LIF (for mESCs) or FGF (for hESCs)
in the presence of vehicle or compounds. Cells were passaged every 48 hr
for five passages (mESCs) and every 7 days for three passages (hESCs),
and the same number of cells was replated. Compounds were replaced every
day. At each passage, cells were fixed and stained in duplicates for alkaline
phosphatase (AP). For every condition, cells were imaged and the number of
alkaline phosphatase positive colonies per well was quantified.
Embryoid Bodies Assay
mESCs were plated in 12-well low attachment plates (Nunc; 300 cells per well)
in mESCmedia in the absence of LIF, supplemented with vehicle or BET inhib-
itors. After 48 hr, cells were imaged and the number of embryoid bodies in each
well was counted (n = 12) and collected for gene expression analysis.
Apoptosis and Cell Cycle Analysis
We seeded 1.1 3 105 mESCs in 6-well gelatin-coated plates in complete me-
diumwith LIF. hESCswere seeded in 6-wellMatrigel-coatedplates in complete
mediumwith FGF. The next day, media was replacedwith completemedium in
the presence of vehicle or BET inhibitors. Compounds were replaced every
day. For apoptosis analysis, on each time point, cells were brought to suspen-
sion and stained for annexin V:phycoerythrin (PE) and 7-aminoactinomycin D
according to the manufacturer protocol (Annexin V: PE Apoptosis Detection
Kit BD Biosciences; 559763). As a positive control for the staining, mESCs
were treated with 500 mM H2O2 for 24 hr. For cell cycle analysis, on each
time point, cells were brought to suspension, washed with PBS, and resus-
pended in 70% ethanol for 30 min at 4C. Cells were spun and resuspendedin 100 ml of fluorescence-activated cell sorting (FACS) buffer with RNase and
phosphatidylinositol stained for 30 min at 37C. A BD LSR II cytometer was
used for data acquisition and Flowjo and Modfit LT software for analysis.
Proliferation Assays
We seeded 43 103 ESCs per well in gelatin or Matrigel-coated 96-well plates
(n = 5/condition) in presence of LIF (mESCs) or FGF (hESCs). After 24 hr, me-
dium was changed to mESC media containing LIF or hESC media containing
FGF and supplemented with vehicle or BET inhibitors. At each time point, cells
were fixed in 100%methanol and stored in PBS at 4C. At the end of the exper-
iment, cells were stained with 0.5% crystal violet. Crystals were dissolved with
15% acetic acid, and optical density was read at 590 nm.
Western Blot
hESCs were harvested in lysis buffer (125 mM Tris [pH 6.8], 4% SDS, and
20% glycerol). Cell lysates (25–30 mg of total proteins) were resolved on
4%–20% Tris-glycine SDS-PAGE gels (Invitrogen) and transferred to nitrocel-
lulose membranes. Membranes were blocked for 1 hr with 5% nonfat milk and
probed with primary antibodies overnight at 4C (OCT4 [Abcam; ab93085] and
tubulin [Sigma]). Membranes were incubated with horseradish-peroxidase-
conjugated secondary antibodies for 1 hr before developing with enhanced
chemiluminescence plus western blotting detection kit (GE Healthcare).
Immunofluorescence Analysis
hESCs grown on coverslips on low-density, MITC-treated MEFs were
analyzed 5 days after FGF, vehicle, or MS436 treatment. Cells were fixed for
10 min with 4% paraformaldehyde, washed three times with PBS, permeabi-
lized with PBS-T (PBS-0.02% and Tween-20), blocked with 1% BSA in PBS,
and incubated 1 hr at room temperature with OCT4 or ECAD (Abcam;
ab1416) antibodies. Samples were washed three times with PBS and incu-
bated for 45minwith Alexa Fluor (Molecular Probes) secondary antibodies. Af-
ter three washes, samples were mounted in Vectashield (Vector Laboratories)
containing DAPI and imaged with a Leica TCS SP5 II confocal microscope.
siRNA Transfection
hESCs, iPSCs, and NTERA-2 cells were transfected with siGENOMENon-Tar-
geting siRNA no. 1 (D-001210-01-20) or siGENOME SMART POOL BRD4
(M-004937-02-0010; Dharmacon) using Lipofectamine 2000 (Invitrogen) ac-
cording to suggested manufacturer procedures. hESCs and iPSCs were
plated on MEFs-coated dishes in the presence of FGF and analyzed 5 days
posttransfection.
Lentiviral Production and ESC Transduction
Lentiviruses were produced in 293T cells, and supernatants were collected
at 24, 48, and 72 hr. Viral particles were concentrated by ultracentrifugation
and stored at 80C. A multiplicity of infection ranging from 10 to 20 was
used to infect ESCs. mESCs were detached and infected with viral superna-
tant in the presence of polybrene (Sigma) at 8 mg/ml concentration. mESCs
incubated with viral supernatants for 2 hr in suspension were seeded in
gelatin-coated dishes and left to recover before puromycin (Sigma; 1 mg/
ml) selection. mESCs were analyzed 5 days postselection. hESCs were de-
tached with Accutase to obtain single-cell suspensions, incubated with viral
supernatants for 2 hr in suspension, and seeded on Matrigel-coated dishes
in the presence of FGF, MITC-MEFs-conditioned medium, and Rock inhibi-
tor. hESCs were analyzed 2 weeks posttransduction for gene expression
and colony morphology.
Plasmids
pGIPZ plasmids targeting human RNA were purchased from Open Bio-
systems. shRNA sequences were subcloned to pH1-IRES-Hygro-GFP re-
porter vector (a gift from Dr. Ruben Hoya Arias; Ivanova et al., 2006). For the
data shown in Figures 6G–6I, the shBRD4 sequence was subcloned to a
pTRIPZ inducible lentiviral vector. pLKO.1 plasmids targeting murine Brd2,
Brd3, Brd4, Med1, Med12, and a nontargeting control were purchased
from Thermo Scientific. See Supplemental Experimental Procedures for se-
quences. pLVX-IRES-Oct4tdTomato and pLVX-IRES-tdTomato vector (Fig-
ures 3I–3K) were a kind gift of M. Stadtfeld.Cell Reports 9, 234–247, October 9, 2014 ª2014 The Authors 245
Teratoma Formation Assay
All mouse experiments were conducted under the Guidelines of the NYU Insti-
tutional Animal Care and Use Committee, protocol no. 120405. mESCs were
infected with lentiviruses containing nontargeting control vector or shRNA-tar-
getingBrd4. Infected cells were selectedwith puromycin (1 mg/ml) for 48 hr and
injected subcutaneously in the flanks of RAG2-deficient mice (Taconic; 1.5 3
106 cells/flank). After 4 weeks, mice were sacrificed and teratomas were ex-
tracted, weighed, fixed in 10% formalin, embedded in paraffin, sectioned,
and stained with hematoxylin and eosin. The following primary antibodies
were used for immunohistochemistry: Ki67 (Master Diagnostica) and NeuN
(Millipore).
Quantitative RT-PCR
Total RNAwas extracted using RNeasy QIAGEN kit according to the manufac-
turer’s instructions. It was then subjected to DNase treatment and retrotran-
scription. Real-time PCR was performed using SYBR green fluorescence
(Roche). hsa-GAPDH and mmu-18S were used as internal standards.
RNA-Sequencing Procedure and Analysis
Deep sequencing of RNA from hESCs FGF or MS436 treated at day 1 and day
5 was performed as described (Rajadhyaksha et al., 2010). See Supplemental
Experimental Procedures for detailed information on samples analysis.
ChIP and ChIP-Seq
Chromatin isolated from FGF-maintained hESCs, vehicle or MS417 treated (at
250 nM concentration for 6 hr), was subjected to ChIP and ChIP-seq protocols
(Ntziachristos et al., 2012). Chromatin from hESCs transduced with a pTRIPZ
vector expressing NTC or shBRD4 sequence was isolated upon 72 hr of doxy-
cycline induction (2 mg/ml) and subjected to ChIP for H3K36me3. See Supple-
mental Experimental Procedures for protocol details and quantitative RT-PCR
(qRT-PCR) primer sequences.
Computational Analysis of RNA-Seq and ChIP-Seq Data Sets
See Supplemental Experimental Procedures for detailed information on data
sources and computational tools used for RNA-seq and ChIP-seq analysis,
peak characterization, generation of Pol II occupancy profiles, transcriptional
elongation, and super-enhancer data analysis.
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The National Center for Biotechnology Information Gene Expression Omnibus
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